THE WOODLANDS, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that four data presentations related to sotagliflozin, an inhibitor of two...
Lexicon preps FDA resubmission for diabetes hopeful Zynquista
Oral presentation delivered at the American Heart Association (AHA) Scientific Sessions 2023 Analysis of clinical data shows statistically significant risk reductions in heart failure and...
Cost-effectiveness data and analyses of financial impact among patients hospitalized for heart failure and treated with INPEFA included as important data selected for presentation INPEFA®...
As previously reported, Express Scripts has also determined that it will list INPEFA as a preferred product on Medicare national formularies starting today, November 1, 2023 INPEFA recently approved...
Presentations from four Lexicon-sponsored studies will highlight data supporting current and potential future use of sotagliflozin INPEFA® (sotagliflozin) recently approved by FDA for treatment of...
Abstracts for cost-effectiveness data and budget-impact model published in the Journal of Managed Care & Specialty Pharmacy (JMCP) INPEFA recently approved by FDA for treatment of heart failure ...
Studies address cost-effectiveness and budget impact of INPEFA, an inhibitor of SGLT2 and SGLT1 INPEFA recently approved by FDA for treatment of heart failure Abstracts published in the Journal of...
INPEFA recently approved by FDA for treatment of heart failure Express Scripts has determined that it will list INPEFA as a preferred product on Medicare national formularies on November 1, 2023 THE...
INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure SCORED was one of two randomized, double-blind, placebo-controlled Phase 3 cardiovascular outcomes studies that led to...